Catalog No.
YHJ12101
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Pro682-Cys859
Predicted molecular weight
20.87 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q76LX8
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
ADAM-TS 13, ADAMTS13, ADAM-TS13, von Willebrand factor-cleaving protease, ADAMTS-13, vWF-cleaving protease, C9orf8, vWF-CP, A disintegrin and metalloproteinase with thrombospondin motifs 13
Is COVID-19 Coagulopathy a Thrombotic Microangiopathy? A Prospective, Observational Study., PMID:40508203
Selected cell receptor genotypes differentially modulate the ABO blood group influence on Factor VIII levels in severe aortic stenosis., PMID:40398046
ADAMTS13 and insulin resistance in systemic sclerosis patients., PMID:40371558
A Disintegrin and Metalloprotease with Thrombospondin Motif, Member 13, and Von Willebrand Factor in Relation to the Duality of Preeclampsia and HIV Infection., PMID:40362344
Early caplacizumab and obinutuzumab enable successful treatment of relapsing thrombotic thrombocytopenic purpura without therapeutic plasma exchange: a case report., PMID:40356910
Pregnancy-related Thrombotic Microangiopathy has a spectrum of underlying causes., PMID:40306205
ADAMTS13 Testing During Clinical Remission of Immune Thrombotic Thrombocytopenic Purpura: A Critical Review., PMID:40273499
Thrombotic Thrombocytopenic Purpura in Oman: Disease Burden and Outcomes., PMID:40248481
Assessment of ferritin and hepcidin levels in splenectomised and non-splenectomised β-thalassemia major patients and exploring a potential correlation with von Willebrand factor and ADAMTS-13., PMID:40232405
Immune status assessment based on plasma proteomics with meta graph convolutional networks., PMID:40211143
Loss of von Willebrand factor large multimers in patients undergoing hemodialysis: A single-center, retrospective study., PMID:40179798
ABO blood group and COVID-19 severity: Associations with endothelial and adipocyte activation in critically ill patients., PMID:40173171
Comparison of the Novel Thrombolytic Constitutively Active ADAMTS13 With Clinical Thrombolytics in a Murine Stroke Model., PMID:40171654
Real-World Analysis of Clinical Characteristics, Treatment Outcomes, and the Novel Predictive Model for Patients with Thrombotic Thrombocytopenic Purpura (TTP) and TTP-Like Syndrome., PMID:40160217
A Descriptive 5-Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA: A Multicenter Study of 390 Disease Episodes From 2017 to 2021., PMID:40145682
Anti-ADAMTS13 Autoantibodies in Immune-Mediated Thrombotic Thrombocytopenic Purpura., PMID:40136473
Development of a protease-resistant ADAMTS13 to improve stability against proteolytic degradation., PMID:40127394
Challenges in managing iTTP: insights into ADAMTS13 inhibitor boosting during caplacizumab therapy., PMID:40105947
Therapeutic switch from plasma to recombinant ADAMTS13 for patients with congenital TTP from Japanese real-world data., PMID:40090002
Real-world evaluation of a novel automated method for measuring ADAMTS-13 activity using the Ceveron s100 analyzer., PMID:40058702
Thrombotic Thrombocytopenic Purpura: A Missed Cause in Stroke Prevention Guidelines., PMID:40052283
Ischemic Stroke in Immune-Mediated Thrombotic Thrombocytopenia Purpura: Diagnostic and Management Challenges., PMID:40052279
Early administration of caplacizumab combined with plasma exchange for thrombotic microangiopathy due to malignant hypertension: a case report., PMID:40029564
The Role of the VWF/ADAMTS13 Axis in the Thromboinflammatory Response in Ischemic Stroke After SARS-CoV2 Infection., PMID:39972966
COVID-19 induced thrombotic thrombocytopenic purpura in a patient with systemic lupus erythematosus: A rare case report., PMID:39969357
Preventative and therapeutic effects of a novel humanized anti-glycoprotein Ibα fragment of antigen-binding region in a murine model of thrombotic thrombocytopenic purpura., PMID:39956431
Arginine Methylation by PRMT1 Affects ADAMTS13 Secretion and Enzymatic Activity., PMID:39945068
ADAMTS13 attenuates renal fibrosis by suppressing thrombospondin 1 mediated TGF-β1/Smad3 activation., PMID:39929281
Impact of new medications on the treatment of immune TTP., PMID:39912777
Role of von Willebrand factor (VWF), platelets, and aberrant flow in the initiation of venous thrombosis., PMID:39908367
Alemtuzumab and thrombotic thrombocytopenic purpura: Analysis of an international surveillance database and systematic literature review., PMID:39883995
ADAMTS13 Improves Endothelial Function and Reduces Inflammation in Diabetic Retinopathy., PMID:39851513
Microangiopathic Hemolytic Anemia: A Rare Complication of Acute Pancreatitis., PMID:39849814
Amelioration of a von Willebrand disease type 2B phenotype in vivo upon treatment with allele-selective siRNAs., PMID:39820471
N-glycan shielded CUB domains of ADAMTS13 prevent binding of C-terminal antibodies in patients with immune-mediated TTP., PMID:39813625
Injury induced endotheliopathy: overview, diagnosis, and management., PMID:39808442
Freeze-dried plasma: Hemostasis and biophysical analyses for damage control resuscitation., PMID:39806922
A mutant complement factor H (W1183R) enhances proteolytic cleavage of von Willebrand factor by ADAMTS-13 under shear., PMID:39798927
GC1126A, a novel ADAMTS13 mutein, evades autoantibodies in immune-mediated thrombotic thrombocytopenic purpura., PMID:39794345
Imbalanced VWF-ADAMTS13 axis contributes to the detrimental impact of a preceding respiratory tract infection on stroke., PMID:39787593
Unraveling antibody-induced structural dynamics in the ADAMTS13 CUB1-2 domains via HDX-MS., PMID:39774799
Plasma Exchange and N-Acetylcysteine Therapy in a Case of Congenital Thrombotic Thrombocytopenic Purpura Presenting With Acute Renal Failure., PMID:39737637
Real-World Retrospective Audit on the Use of the TechnoClone TECHNOSCREEN ADAMTS-13 Assay in the Diagnostic Process for Thrombotic Thrombocytopenic Purpura at LabPlus, New Zealand., PMID:39692349
Primary Thrombotic Microangiopathy in Pediatric Patients., PMID:39691204
Complex immunogenicity assessment in caplacizumab-treated patients with immune-mediated thrombotic thrombocytopenic purpura who have received plasma exchange., PMID:39687921
Evaluating the potential for iodinated radiocontrast agents to interfere with ADAMTS13 activity testing via fluorescence resonance energy transfer methodology., PMID:39657035
A novel automated chemiluminescent enzyme immunoassay for ADAMTS-13 activity enables accompanying measurements of the inhibitory autoantibodies., PMID:39662872
Increased Platelet Adhesiveness in Patients with Venous Thromboembolic Disease., PMID:39619107
Hereditary thrombotic thrombocytopenic purpura mimicking immune thrombocytopenia was revealed by miscarriage-novel compound heterozygous mutations in hTTP., PMID:39614241
Real-world safety and efficacy of rADAMTS13 in the treatment of congenital thrombotic thrombocytopenic purpura in pediatric patients in Poland., PMID:39603385
For research use only. Not for human or drug use.
